Equities analysts expect that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will announce earnings per share of ($0.09) for the current quarter, Zacks reports. Zero analysts have issued estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.10). ZIOPHARM Oncology reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive year over year growth rate of 40%. The firm is expected to announce its next earnings report on Thursday, May 9th.

On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.35) to ($0.26). For the next year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for ZIOPHARM Oncology.

A number of equities research analysts have issued reports on ZIOP shares. BidaskClub upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Friday, December 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $4.92.

Several institutional investors and hedge funds have recently bought and sold shares of ZIOP. Amalgamated Bank bought a new position in ZIOPHARM Oncology in the 4th quarter valued at approximately $37,000. Allred Capital Management LLC bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $40,000. SG Americas Securities LLC bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $46,000. Legal & General Group Plc increased its position in shares of ZIOPHARM Oncology by 30.6% during the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 6,054 shares during the period. Finally, Gamble Jones Investment Counsel bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter valued at about $56,000. Institutional investors own 38.01% of the company’s stock.

Shares of ZIOP traded down $0.07 during trading hours on Monday, hitting $4.00. The company had a trading volume of 1,805,803 shares, compared to its average volume of 1,738,243. The firm has a market capitalization of $660.52 million, a PE ratio of -8.33 and a beta of 2.59. ZIOPHARM Oncology has a 12 month low of $1.56 and a 12 month high of $5.00.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Featured Story: Quick Ratio

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.